Study title: Evaluation of single agent rasburicase in treatment/ prevention of hyperuricemia associated with tumor lysis syndrome in adult and paediatric patients with lymphoma/ leukemia/solid tumor or malignancies at their first relapse or refractory disease
| Type of medicine: Centrally authorised medicines | |||||
| Therapeutic area: Pathological Conditions, Signs and Symptoms | |||||
| Brands: | |||||
| MAH holders: | |||||
| Assessment: | |||||
| Active substance: rasburicase | |||||
| ATC code: V03AF07 | |||||
| Document link: | |||||
| Document date: 2011-09-22 | |||||
| Study number: EFC5339 | |||||
| EudraCT number: | |||||
| Scope of study: CLINICAL | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |